CYTODYN INC. DL -,01 WKN: A0YHA5 ISIN: US23283M1018 Kürzel: 296 Forum: Aktien Thema: Hauptdiskussion

🙋‍♂️

https://www.cytodyn.com/newsroom/press-releases/detail/371/cytodyn-to-deliver-presentation-at-biotech-showcase

👀

CytoDyn Reports Early, But Strong Positive Clinical Responses for Two Patients, One in Metastatic Breast Cancer and One in Metastatic Triple-Negative Breast Cancer Trials  Download as PDFDecember 23, 2019 6:00am EST Objective clinical responses in these two patients treated with leronlimab (PRO 140) lead to plans for imminent filing of a Breakthrough Therapy Designation Application while trial enrollment efforts continue at much higher pace https://www.cytodyn.com/newsroom/press-releases/detail/370/cytodyn-reports-early-but-strong-positive-clinical

CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV  December 17, 2019 4:36pm EST In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera will also make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications https://www.cytodyn.com/newsroom/press-releases/detail/369/cytodyn-signs-definitive-agreements-with-vyera

CytoDyn Reports Strong Positive Preclinical Data to Demonstrate Potential of Leronlimab in Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Humanized Mouse Model https://www.cytodyn.com/newsroom/press-releases/detail/366/cytodyn-reports-strong-positive-preclinical-data-to

CytoDyn's Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies CytoDyn will file for expanded access IND for patients with pancreatic, prostate, lung, breast, liver and melanoma cancers https://www.cytodyn.com/newsroom/press-releases/detail/365/cytodyns-lead-product-candidate-leronlimab-pro-140

Super Ergebnisse für Leronlimab und Fast track designation. https://www.google.com/amp/s/www.proactiveinvestors.com/companies/amp/news/906857

https://www.google.com/amp/s/seekingalpha.com/amp/article/4299047-cytodyn-less

CytoDyn's triple-negative breast cancer drug leronlimab given to first patient in clinical trial https://www.google.com/amp/s/www.proactiveinvestors.com/companies/amp/news/903769

CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab https://www.globenewswire.com/news-release/2019/09/04/1910587/0/en/CytoDyn-Files-an-IND-and-a-Phase-2-Protocol-with-the-FDA-for-the-Treatment-of-NASH-with-Leronlimab.html

CytoDyn to Present at RHK Capital 2019 Disruptive Growth Conference Dr. Pourhassan will present on, among other things, the potential to increase leronlimab’s half-life so that it may be able to be administered only once a month, and pre-clinical study results pertaining to the potential for leronlimab to reduce liver fibrosis, which is one of the clinical manifestations of non-alcoholic steatohepatitis (NASH). https://www.globenewswire.com/news-release/2019/08/29/1908463/0/en/CytoDyn-to-Present-at-RHK-Capital-2019-Disruptive-Growth-Conference.html

CytoDyn Joins The Stock Day Podcast to Discuss Phase 3 Trials for Their HIV Program Jolly asked about the Company's plans for potential partnerships or licensing. Dr. Pourhassan shared that the Company is very close to signing a licensing agreement, which represents an important step towards the production of their HIV program. To close the interview, Jolly noted that the Company is exceptionally undervalued and represents a great opportunity for investors interested in this space. https://finance.yahoo.com/news/cytodyn-joins-stock-day-podcast-120000211.html

CytoDyn Provides Update on Dose Escalating Trial with Leronlimab for HIV Monotherapy for a Potential Pivotal Trial 564 patients have been enrolled in monotherapy trials to date with over 150 patients hitting the benchmark of one-year of sustained viral suppression The response rate post-10 weeks of monotherapy is 68% with 350 mg dose, 94% with 525 mg and 85% with 700 mg https://www.globenewswire.com/news-release/2019/08/14/1901595/0/en/CytoDyn-Provides-Update-on-Dose-Escalating-Trial-with-Leronlimab-for-HIV-Monotherapy-for-a-Potential-Pivotal-Trial.html

CytoDyn Files a Phase 2 Protocol with the FDA for Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer This is a single arm study with 30 patients designed to test the hypothesis that the combination of leronlimab, administered as a subcutaneous injection, and Regorafenib, administered orally, will increase progression-free survival in patients with CCR5-positive metastatic colorectal cancer. “This is the third clinical program that CytoDyn has underway in the oncology space,” stated, CytoDyn President and CEO, Nader Pourhassan, Ph.D. “We recently announced the first injection in our clinical trial using leronlimab to treat metastatic triple-negative breast cancer (rmTNBC), under the supervision of Jacob Lalezari, M.D.  In addition, our Phase 1b/2 trial using leronlimab in treatment-naïve mTNBC patients is under the supervision of Massimo Cristofanilli, M.D. professor of Medicine in the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine.”    “With results from multiple pre-clinical studies in various cancer indications, including MBC and mCRC, we are optimistic about the potential of leronlimab to provide a new therapeutic option for individuals diagnosed with invasive cancer each year in the United States.  We again thank the patients who have agreed to participate in our trials and endeavor to provide each of them with clinical benefit,” concluded Dr. Pourhassan. https://www.globenewswire.com/news-release/2019/08/08/1899023/0/en/CytoDyn-Files-a-Phase-2-Protocol-with-the-FDA-for-Leronlimab-PRO-140-and-Regorafenib-as-a-Combination-Therapy-for-Metastatic-Colorectal-Cancer.html

wow... 👏🏻 bin gespannt ob das klappt Danke für die Info